AndrewLHimelsteinMD

Oncology • Newark, DE

Assistant Clinical Professor of Medicine, Thomas Jefferson University

Join to view full profile

Are you Dr. Himelstein?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 87 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
4701 Ogletown Stanton Rd
Ste 3400
Newark, DE 19713
Phone+1 302-366-1200

Fax+1 302-366-1700

Summary

Dr. Andrew Himelstein, MD is an oncologist in Newark, Delaware. He is currently licensed to practice medicine in Delaware, New Jersey, and Pennsylvania. He is affiliated with ChristianaCare and St. Francis Hospital.

Education & Training

New York Presbyterian Hospital (Columbia Campus)Fellowship, Hematology and Medical Oncology, 1988 - 1991
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1985 - 1988
Washington University in St. Louis School of MedicineClass of 1985

Certifications & Licensure

DE State Medical License 1991 - 2025
PA State Medical License 1991 - 2024
NJ State Medical License 1991 - 2005
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Hospice and Palliative Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2010-2014
America's Top Doctors for Cancer Castle Connolly, 2009-2013
Fellow (FACP) American College of Physicians, 1998

Clinical Trials

Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement Start of enrollment: 2009 Mar 01
Completed
Phase 3

Publications & Presentations

PubMed

92 citations
Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials.
Ethan Basch, Amylou C. Dueck, Lauren J. Rogak, Lori M. Minasian, William Kevin Kelly
JAMA Oncology. 2017-08-01
219 citations
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.
Andrew L. Himelstein, Jared C. Foster, James L. Khatcheressian, John D. Roberts, Drew K. Seisler
JAMA. 2017-01-03
43 citations
Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALG...
Charles L. Shapiro, James P. Moriarty, Stacie B. Dusetzina, Andrew L. Himelstein, Jared C. Foster
Journal of Clinical Oncology. 2017-10-12

Press Mentions

COMMENTARY: Start the Conversation with Your DoctorFebruary 17th, 2019
Less Frequent Zoledronic Acid Not Linked to Increased Skeletal Events for Patients with Bone MetastasesJanuary 8th, 2017
Powerful Drug for Advanced Cancers May Need Less Frequent DosingJanuary 4th, 2017

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American College of Physicians - ACP
Fellow